Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (9403)
All Articles published online
|
Publishing Process of This Article
|
Mar 7, 2017 (publication date) through May 5, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Langness JA, Nguyen M, Wieland A, Everson GT, Kiser JJ. Optimizing hepatitis C virus treatment through pharmacist interventions: Identification and management of drug-drug interactions. World J Gastroenterol 2017; 23(9): 1618-1626 [PMID: 28321163 DOI: 10.3748/wjg.v23.i9.1618] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v23/i9/1618.htm |
| Number | Citing Articles |
| 1 |
Safiya S Naidjate, Andrew R Zullo, Ruth Dapaah-Afriyie, Michelle L Hersey, Brandon D L Marshall, Richelle Manalang Winkler, Christine Berard-Collins. Comparative effectiveness of pharmacist care delivery models for hepatitis C clinics. American Journal of Health-System Pharmacy 2019; 76(10): 646 doi: 10.1093/ajhp/zxz034
|
| 2 |
David Back, Pamela Belperio, Mark Bondin, Francesco Negro, Andrew H. Talal, Caroline Park, ZhenZhen Zhang, Brett Pinsky, Eric Crown, Federico J. Mensa, Fiona Marra. Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis. Journal of Viral Hepatitis 2019; 26(8): 951 doi: 10.1111/jvh.13110
|
| 3 |
Antoni Sicras Mainar, Ruth Navarro Artieda, Ignacio Hernández, Ramón Morillo. Prevalence of the potential drug–drug interactions between pangenotypic direct-acting antivirals and the concomitant medications associated with patients with chronic hepatitis C virus infection in Spain. Gastroenterología y Hepatología (English Edition) 2019; 42(8): 465 doi: 10.1016/j.gastre.2019.09.001
|
| 4 |
Stuart C. Gordon, Ankita Kaushik, Benjamin Chastek, Amy Anderson, Alon Yehoshua. Characteristics associated with receipt of treatment among patients diagnosed with chronic hepatitis C virus. Journal of Viral Hepatitis 2023; 30(9): 756 doi: 10.1111/jvh.13860
|
| 5 |
Antoni Sicras Mainar, Ruth Navarro Artieda, Ignacio Hernández, Ramón Morillo. Prevalencia de las potenciales interacciones medicamentosas entre los antivirales de acción directa pangenotípicos y la medicación concomitante asociada a los pacientes con infección del virus de la hepatitis C crónica en España. Gastroenterología y Hepatología 2019; 42(8): 465 doi: 10.1016/j.gastrohep.2019.03.014
|
| 6 |
E Chamorro-de-Vega, C G Rodríguez-González, Álvaro Giménez-Manzorro, A Herranz, M Sanjurjo. Hepatitis C virus infection and the role of a pharmaceutical care program. American Journal of Health-System Pharmacy 2020; 77(6): 479 doi: 10.1093/ajhp/zxz266
|
| 7 |
Sidra Noor, Mohammad Ismail, Zahid Ali. Potential drug-drug interactions among pneumonia patients: do these matter in clinical perspectives?. BMC Pharmacology and Toxicology 2019; 20(1) doi: 10.1186/s40360-019-0325-7
|
| 8 |
Sidra Noor, Mohammad Ismail, Iqbal Haider, Faiza Khadim. Drug-Drug Interactions in Hepatitis Patients: Do these Interactions Matter in Clinical Perspectives?. Annals of Hepatology 2018; 17(6): 1001 doi: 10.5604/01.3001.0012.7200
|
| 9 |
Hala Mohsen Abdullatif, Rania Ramzi, Engy Adel Mogahed, Carolyne Morcos Ghobrial, Basma Abd El Rasheed Abd El Zaher, Mona S. El Raziky, Hanaa Mostafa El-Karaksy. Drug–Drug Interactions in Children and Adolescents Receiving Ledipasvir/Sofosbuvir for the Treatment of Hepatitis C Virus Infection. Clinical Drug Investigation 2019; 39(9): 857 doi: 10.1007/s40261-019-00805-5
|
| 10 |
Carlos Roncero, Jose Luis Villegas, Maria Martínez-Rebollar, Maria Buti. The pharmacological interactions between direct-acting antivirals for the treatment of chronic hepatitis c and psychotropic drugs. Expert Review of Clinical Pharmacology 2018; 11(10): 999 doi: 10.1080/17512433.2018.1519392
|
| 11 |
Ivana Mikolasevic, Tajana F. Kanizaj, Dorotea Bozic, Petra Puz, Sanja S. Shapeski, Zeljko Puljiz, Delfa Radic-Kristo, Milos Lalovac, Maja Mijic, Bozena Delija, Toni Juric, Ivan Bogadi, Lucija Virovic-Jukic. Metabolism of Direct-acting Antiviral Agents (DAAs) in Hepatitis C Therapy: A Review of the Literature. Current Drug Metabolism 2021; 22(2): 89 doi: 10.2174/1389200221999201214224126
|
| 12 |
Michelle Duong, Chris Delcher, Patricia R. Freeman, April M. Young, Hannah L.F. Cooper. Attitudes toward pharmacy‐based HCV/HIV testing among people who use drugs in rural Kentucky. The Journal of Rural Health 2022; 38(1): 93 doi: 10.1111/jrh.12564
|
| 13 |
Chen‐Hua Liu, Ming‐Lung Yu, Cheng‐Yuan Peng, Tsai‐Yuan Hsieh, Yi‐Hsiang Huang, Wei‐Wen Su, Pin‐Nan Cheng, Chih‐Lin Lin, Ching‐Chu Lo, Chi‐Yi Chen, Jyh‐Jou Chen, Qian Ma, Craig Brooks‐Rooney, Jia‐Horng Kao. Comorbidities, concomitant medications and potential drug‐drug interactions with interferon‐free direct‐acting antiviral agents in hepatitis C patients in Taiwan. Alimentary Pharmacology & Therapeutics 2018; 48(11-12): 1290 doi: 10.1111/apt.15011
|
| 14 |
Nicola Imperatore, Fabiana Castiglione, Antonio Rispo, Anna Sessa, Nicola Caporaso, Filomena Morisco. Timing Strategies of Direct-Acting Antivirals and Biologics Administration in HCV-Infected Subjects with Inflammatory Bowel Diseases. Frontiers in Pharmacology 2017; 8 doi: 10.3389/fphar.2017.00867
|
| 15 |
Ashley A Sabourin, Kaleigh K Fisher-Grant, Adam R Saulles, Rima A Mohammad. Evaluation of a specialty hepatitis C virus telephone pharmacy service. American Journal of Health-System Pharmacy 2021; 78(Supplement_2): S38 doi: 10.1093/ajhp/zxaa423
|
| 16 |
Miriam Coghlan, Aisling O’Leary, Gail Melanophy, Colm Bergin, Suzanne Norris. Pharmacist-led pre-treatment assessment, management and outcomes in a Hepatitis C treatment patient cohort. International Journal of Clinical Pharmacy 2019; 41(5): 1227 doi: 10.1007/s11096-019-00876-6
|
| 17 |
Autumn D. Zuckerman, Andrew Douglas, Kristen Whelchel, Leena Choi, Joshua DeClercq, Cody A. Chastain, Tatsuo Kanda. Pharmacologic management of HCV treatment in patients with HCV monoinfection vs. HIV/HCV coinfection: Does coinfection really matter?. PLOS ONE 2019; 14(11): e0225434 doi: 10.1371/journal.pone.0225434
|
| 18 |
Sidra Noor, Mohammad Ismail, Fahadullah Khan. Drug safety in hospitalized patients with tuberculosis: Drug interactions and adverse drug effects. The Clinical Respiratory Journal 2021; 15(1): 97 doi: 10.1111/crj.13276
|
| 19 |
Bijou R. Hunt, Hollyn Cetrone, Sharon Sam, Nancy R. Glick. Outcomes of a Pharmacist-Led Hepatitis C Virus Treatment Program in an Urban Safety-Net Health System, Chicago, 2017-2019. Public Health Reports 2022; 137(4): 702 doi: 10.1177/00333549211015664
|
| 20 |
Andreina A. Ottman, Mary L. Townsend, Mohamed G. Hashem, Vincent P. DiMondi, Rachel B. Britt. Incidence of Drug Interactions Identified by Clinical Pharmacists in Veterans Initiating Treatment for Chronic Hepatitis C Infection. Annals of Pharmacotherapy 2018; 52(8): 763 doi: 10.1177/1060028018766507
|
| 21 |
Luis Margusino-Framiñán, Purificación Cid-Silva, Victor Giménez-Arufe, Cristina Mondelo-García, Carla Fernández-Oliveira, Álvaro Mena-de-Cea, Isabel Martín-Herranz, Ángeles Castro-Iglesias. Influence of drug–drug interactions on effectiveness and safety of direct-acting antivirals against hepatitis C virus. European Journal of Hospital Pharmacy 2021; 28(1): 16 doi: 10.1136/ejhpharm-2019-001889
|
| 22 |
S Bourgeois, JP Mulkay, M Cool, X Verhelst, G Robaeys, L Lasser, V Lefebvre, I Colle, C Van Steenkiste, J Decaestecker, S Coulon, K Venken, T Vanwolleghem. Comorbidities and concomitant medications in patients with chronic hepatitis C virus infection receiving second-generation direct-acting antiviral regimens in Belgium : an observational study. Acta Gastro Enterologica Belgica 2021; 84(1): 33 doi: 10.51821/84.1.851
|
| 23 |
Lucas Miyake Okumura, Mariana Rosim, Bruno Salgado Riveros, Rosa Camilla Lucchetta, Gabriel Ogata Pedro, Marcelo Eidi Nita. A glance in hepatitis C policy in Brazil: Access and performance. Ciência & Saúde Coletiva 2018; 23(2): 675 doi: 10.1590/1413-81232018232.24292017
|
| 24 |
Sidra Noor, Mohammad Ismail, Faiza Khadim. Potential drug–drug interactions associated with adverse clinical outcomes and abnormal laboratory findings in patients with malaria. Malaria Journal 2020; 19(1) doi: 10.1186/s12936-020-03392-5
|
| 25 |
Meng Hsuan Kuo, Chih-Wei Tseng, Chi-Hui Lee, Ya-Ching Yang, Hsin-Ju Wu, Hsiu-Ju Lin, Ya-Lan Chu, Yen-Chun Chen, Kuo-Chih Tseng. Identification and management of contraindicated drug–drug interactions through pharmaceutical care programs: Experience in direct-acting antivirals therapy. Journal of the Formosan Medical Association 2022; 121(1): 58 doi: 10.1016/j.jfma.2021.01.008
|
| 26 |
Yeba H. Adje, Kristina M. Brooks, Jose R. Castillo-Mancilla, David L. Wyles, Peter L. Anderson, Jennifer J. Kiser. The use of technology-based adherence monitoring in the treatment of hepatitis C virus. Therapeutic Advances in Infectious Disease 2022; 9: 204993612210956 doi: 10.1177/20499361221095664
|
| 27 |
Chun-Jen Liu, Kuo-Chih Tseng, Ching-Chu Lo, I-Hao Tseng, Pin-Nan Cheng. Limited drug–drug interaction of elbasvir/grazoprevir for chronic hepatitis C. Journal of the Formosan Medical Association 2020; 119(5): 933 doi: 10.1016/j.jfma.2019.09.011
|
| 28 |
А. В. Волкова, А. А. Ноздріна. Analysis of the awareness by healthcare professionals and the public about viral hepatitis in the context of decentralisation of diagnostics. Farmatsevtychnyi zhurnal 2023; (5): 20 doi: 10.32352/0367-3057.5.23.03
|
| 29 |
David E Koren, Autumn Zuckerman, Robyn Teply, Nadia A Nabulsi, Todd A Lee, Michelle T Martin. Expanding Hepatitis C Virus Care and Cure: National Experience Using a Clinical Pharmacist–Driven Model. Open Forum Infectious Diseases 2019; 6(7) doi: 10.1093/ofid/ofz316
|
| 30 |
Po-Yao Hsu, Yu-Ju Wei, Jia-Jung Lee, Sheng-Wen Niu, Jiun-Chi Huang, Cheng-Ting Hsu, Tyng-Yuan Jang, Ming-Lun Yeh, Ching-I Huang, Po-Cheng Liang, Yi-Hung Lin, Ming-Yen Hsieh, Meng-Hsuan Hsieh, Szu-Chia Chen, Chia-Yen Dai, Zu-Yau Lin, Shinn-Cherng Chen, Jee-Fu Huang, Jer-Ming Chang, Shang-Jyh Hwang, Wan-Long Chuang, Chung-Feng Huang, Yi-Wen Chiu, Ming-Lung Yu. Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis. Clinical and Molecular Hepatology 2021; 27(1): 186 doi: 10.3350/cmh.2020.0180
|
| 31 |
Lindsay Chalmers. Hepatitis C: prescribing challenges in the era of new direct-acting antivirals. Journal of Prescribing Practice 2019; 1(2): 80 doi: 10.12968/jprp.2019.1.2.80
|
| 32 |
Juliemar Aponte, Patrick J. Silva, Kenneth S. Ramos. Comprehensive Precision Medicine. 2024; : 221 doi: 10.1016/B978-0-12-824010-6.00030-7
|
| 33 |
Lena A. Mikolas, Kimberly Jacques, Mostaqul Huq, Charles Krasner, Scott E. Mambourg. Utilizing Clinical Pharmacist Specialist to Manage Hepatitis C Virus Patients on Direct-Acting Antiviral Therapy. Journal of Pharmacy Practice 2019; 32(6): 655 doi: 10.1177/0897190018777345
|
| 34 |
Austin Chan, Lawrence Park, Lauren F Collins, Curtis Cooper, Michael Saag, Douglas Dieterich, Mark Sulkowski, Susanna Naggie. Correlation Between Tenofovir Drug Levels and the Renal Biomarkers RBP-4 and ß2M in the ION-4 Study Cohort. Open Forum Infectious Diseases 2019; 6(1) doi: 10.1093/ofid/ofy273
|
| 35 |
Daniel J. Ruzicka, Jumpei Tetsuka, Go Fujimoto, Tatsuya Kanto. Comorbidities and co-medications in populations with and without chronic hepatitis C virus infection in Japan between 2015 and 2016. BMC Infectious Diseases 2018; 18(1) doi: 10.1186/s12879-018-3148-z
|
| 36 |
Elena González-Colominas, Marc Batlle, Inés Monge-Escartín, Xavier Duran, Anna Viu, Marta de Antonio-Cuscó, Santiago Grau, Xavier Bessa, Jose Antonio Carrión. Impact of HCV cure with drug-acting antivirals in the use of concomitant medication and lipid profile: follow-up data 2 years after the sustained virological response. European Journal of Gastroenterology & Hepatology 2021; 32(2): 214 doi: 10.1097/MEG.0000000000001714
|
| 37 |
Roheena Zafar, Inayat Ur Rehman, Yasar Shah, Long Chiau Ming, Hui Poh Goh, Khang Wen Goh, Muhammad Junaid Farrukh. Comparative analysis of potential drug-drug interactions in a public and private hospital among chronic kidney disease patients in Khyber Pakhtunkhwa: A retrospective cross-sectional study. PLOS ONE 2023; 18(9): e0291417 doi: 10.1371/journal.pone.0291417
|
| 38 |
Sidra Noor, Mohammad Ismail, Fahadullah Khan. Potential Drug-Drug Interactions in Patients With Urinary Tract Infections: A Contributing Factor in Patient and Medication Safety. Frontiers in Pharmacology 2019; 10 doi: 10.3389/fphar.2019.01032
|